Lopinavir
FDA-approved product (capsule, oral).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- HIV infection
- HIV-1 infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- Anti-infective classification
- Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.
Repurposing investigation
Lopinavir reaches ≥40% AI-predicted activity against MRSA and M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.
AI-predicted activity
AI prediction · nothing measured- MRSA40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lopinavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nafarelin AcetateExisting use: Endometriosis58.6% AI-predicted activityagainst E. coli12 registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more58.5% AI-predicted activityagainst E. coli50+ registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction58.3% AI-predicted activityagainst E. coli50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more58.1% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder57.8% AI-predicted activityagainst E. coliNo documented evidence found
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction57.4% AI-predicted activityagainst E. coli1 registered study
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more57.2% AI-predicted activityagainst E. coli16 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma57.2% AI-predicted activityagainst E. coli50+ registered studies
- Cisapride MonohydrateExisting use: Gastrointestinal disease56.3% AI-predicted activityagainst E. coli5 registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension56.3% AI-predicted activityagainst E. coli50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm56.0% AI-predicted activityagainst E. coli50+ registered studies
- AtogepantExisting use: Migraine disorder56.0% AI-predicted activityagainst E. coli36 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
NCT00028301 · start 2001-02
Registered record
- Registry ID
- NCT00028301
- Conditions
- HIV Infections
- Interventions
- Atazanavir; Lopinavir/Ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-02
- Completion
- 2003-09
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionAtazanavir; Lopinavir/RitonavirPhasePhase 3Registry statusCompletedSpecial Investigation of Kaletra in Pregnant Women
NCT01076985 · start 2000-12
Registered record
- Registry ID
- NCT01076985
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Lopinavir/ritonavir (Kaletra)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2000-12
- Completion
- 2010-12
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHuman Immunodeficiency VirusInterventionLopinavir/ritonavir (Kaletra)PhaseNot recordedRegistry statusCompletedA Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
NCT00038636 · start 2000-09
Registered record
- Registry ID
- NCT00038636
- Conditions
- HIV Infections
- Interventions
- Lopinavir/ritonavir; Ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2000-09
- Completion
- Not recorded
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionLopinavir/ritonavir; RitonavirPhasePhase 3Registry statusCompletedDual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
NCT00028366
Registered record
- Registry ID
- NCT00028366
- Conditions
- HIV Infections
- Interventions
- Fosamprenavir; Lopinavir/Ritonavir; Ritonavir; Tenofovir disoproxil fumarate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2005-07
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionFosamprenavir; Lopinavir/Ritonavir; Ritonavir; Tenofovir disoproxil fumaratePhaseNot applicableRegistry statusCompletedA Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
NCT00036452
Registered record
- Registry ID
- NCT00036452
- Conditions
- HIV Infections
- Interventions
- lopinavir/ritonavir; emtricitabine; stavudine; tenofovir DF
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2006-01
- Enrolment
- 402
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionlopinavir/ritonavir; emtricitabine; stavudine; tenofovir DFPhasePhase 2Registry statusCompleted